HU224956B1 - Pharmaceutical antiviral composition comprising glycyrrhizic acid and at least one protein endowed with antiviral activity - Google Patents

Pharmaceutical antiviral composition comprising glycyrrhizic acid and at least one protein endowed with antiviral activity Download PDF

Info

Publication number
HU224956B1
HU224956B1 HU0002985A HUP0002985A HU224956B1 HU 224956 B1 HU224956 B1 HU 224956B1 HU 0002985 A HU0002985 A HU 0002985A HU P0002985 A HUP0002985 A HU P0002985A HU 224956 B1 HU224956 B1 HU 224956B1
Authority
HU
Hungary
Prior art keywords
lysozyme
antiviral
inhibition
lactoferrin
cells
Prior art date
Application number
HU0002985A
Other languages
English (en)
Hungarian (hu)
Inventor
Raffaello Pompei
Mario Pinza
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acraf filed Critical Acraf
Publication of HUP0002985A2 publication Critical patent/HUP0002985A2/hu
Publication of HUP0002985A3 publication Critical patent/HUP0002985A3/hu
Publication of HU224956B1 publication Critical patent/HU224956B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU0002985A 1997-05-14 1998-05-06 Pharmaceutical antiviral composition comprising glycyrrhizic acid and at least one protein endowed with antiviral activity HU224956B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT97MI001119A IT1291366B1 (it) 1997-05-14 1997-05-14 Composizione farmaceutica antivirale comprendente acido glicirrizico ed almeno una proteina dotata di attivita' antivirale
PCT/EP1998/002797 WO1998051334A1 (en) 1997-05-14 1998-05-06 Pharmaceutical antiviral composition comprising glycyrrhizic acid and at least one protein endowed with antiviral activity

Publications (3)

Publication Number Publication Date
HUP0002985A2 HUP0002985A2 (hu) 2001-01-29
HUP0002985A3 HUP0002985A3 (en) 2001-04-28
HU224956B1 true HU224956B1 (en) 2006-04-28

Family

ID=11377123

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0002985A HU224956B1 (en) 1997-05-14 1998-05-06 Pharmaceutical antiviral composition comprising glycyrrhizic acid and at least one protein endowed with antiviral activity

Country Status (26)

Country Link
US (1) US6329339B1 (enExample)
EP (1) EP0980254B1 (enExample)
JP (2) JP2001525814A (enExample)
KR (1) KR100592193B1 (enExample)
CN (1) CN1114447C (enExample)
AR (1) AR012849A1 (enExample)
AT (1) ATE212232T1 (enExample)
AU (1) AU740944B2 (enExample)
BG (1) BG64748B1 (enExample)
CA (1) CA2289550A1 (enExample)
CZ (1) CZ291932B6 (enExample)
DE (1) DE69803565T2 (enExample)
DK (1) DK0980254T3 (enExample)
EA (1) EA003126B1 (enExample)
ES (1) ES2170501T3 (enExample)
GE (1) GEP20022672B (enExample)
HU (1) HU224956B1 (enExample)
IL (2) IL132651A0 (enExample)
IT (1) IT1291366B1 (enExample)
PL (1) PL189218B1 (enExample)
PT (1) PT980254E (enExample)
SK (1) SK283584B6 (enExample)
TR (1) TR199902730T2 (enExample)
UA (1) UA63955C2 (enExample)
WO (1) WO1998051334A1 (enExample)
ZA (1) ZA983917B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7151082B2 (en) * 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7304034B2 (en) * 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
AU2003225073A1 (en) * 2002-04-18 2003-11-03 The University Of Iowa Research Foundation Methods of inhibiting and treating bacterial biofilms by metal chelators
US7696169B2 (en) * 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
AU2004272607B2 (en) * 2003-09-11 2008-11-06 Cornerstone Therapeutics Inc. Monoclonal antibodies against HMGB1
EP1909834A2 (en) * 2005-07-18 2008-04-16 Critical Therapeutics, Inc. Use of hmgb1 antagonists for the treatment of inflammatory skin conditions
US20080311122A1 (en) * 2005-11-28 2008-12-18 Medimmune, Llc Antagonists of Hmgb1 and/or Rage and Methods of Use Thereof
IT1391170B1 (it) * 2008-08-07 2011-11-18 D M G Italia S R L Composizione topica intra-nasale utilizzabile in caso di ostruzione nasale
CA2809031C (en) * 2010-08-25 2018-10-16 Weijian Zhang Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis
US9416151B2 (en) 2010-08-25 2016-08-16 Lurong ZHANG Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis
JP5806434B1 (ja) 2014-02-21 2015-11-10 国立大学法人東京海洋大学 ノロウィルス不活化剤及びその製造方法、ノロウィルス不活化方法、ノロウィルス不活化用リゾチーム類の製造方法、ノロウィルス感染の予防薬又は治療薬、並びにノロウィルス不活化用皮膚外用剤
US12447166B2 (en) 2016-02-25 2025-10-21 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
MX2018010198A (es) 2016-02-25 2019-06-12 Applied Biological Laboratories Inc Composiciones y metodos para proteger contra patogenos e irritantes transportados por el aire.
CN109022351B (zh) * 2018-09-28 2021-10-19 广州奇龙生物科技有限公司 重组人溶菌酶的新应用
JP7543427B2 (ja) * 2020-04-27 2024-09-02 広州新創憶薬物臨床研究有限公司 抗新型コロナウイルス感染症の医薬品、食品、及び使用
CN112135625B (zh) * 2020-04-27 2021-07-06 广州新创忆药物临床研究有限公司 一种预防或治疗covid-19新冠肺炎的药物及其应用
WO2021217702A1 (zh) * 2020-04-27 2021-11-04 广州新创忆药物临床研究有限公司 一种预防或治疗covid-19新冠肺炎的药物、食物及其应用
MX2021005280A (es) * 2021-05-04 2022-02-23 Spv Timser S A P I De C V Composicion farmaceutica que contiene triterpenoides pentaciclicos.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH085800B2 (ja) * 1986-12-19 1996-01-24 エーザイ株式会社 塩化リゾチ−ム及びグリチルリチン酸ジカリウム含有水溶液製剤
JP2838720B2 (ja) * 1989-10-31 1998-12-16 ゼリア新薬工業株式会社 安定な点眼剤
JP4056099B2 (ja) * 1996-05-09 2008-03-05 森永乳業株式会社 水生動物の寄生生物性疾患の予防および治療剤

Also Published As

Publication number Publication date
HK1028347A1 (en) 2001-02-16
PL336802A1 (en) 2000-07-17
CN1255859A (zh) 2000-06-07
PT980254E (pt) 2002-07-31
CZ291932B6 (cs) 2003-06-18
PL189218B1 (pl) 2005-07-29
HUP0002985A3 (en) 2001-04-28
JP2009102370A (ja) 2009-05-14
AU740944B2 (en) 2001-11-15
EP0980254A1 (en) 2000-02-23
ES2170501T3 (es) 2002-08-01
CZ399199A3 (cs) 2000-04-12
EA199901024A1 (ru) 2000-06-26
WO1998051334A1 (en) 1998-11-19
DE69803565T2 (de) 2002-08-08
JP2001525814A (ja) 2001-12-11
ITMI971119A0 (enExample) 1997-05-14
IL132651A0 (en) 2001-03-19
SK154499A3 (en) 2000-08-14
DK0980254T3 (da) 2002-05-06
ATE212232T1 (de) 2002-02-15
UA63955C2 (uk) 2004-02-16
AR012849A1 (es) 2000-11-22
CN1114447C (zh) 2003-07-16
EA003126B1 (ru) 2003-02-27
KR20010012419A (ko) 2001-02-15
BG64748B1 (bg) 2006-02-28
SK283584B6 (sk) 2003-10-07
TR199902730T2 (xx) 2000-02-21
ZA983917B (en) 1998-11-09
BG103968A (en) 2000-07-31
EP0980254B1 (en) 2002-01-23
IL132651A (en) 2006-10-31
AU7764698A (en) 1998-12-08
KR100592193B1 (ko) 2006-06-23
HUP0002985A2 (hu) 2001-01-29
ITMI971119A1 (it) 1998-11-14
CA2289550A1 (en) 1998-11-19
US6329339B1 (en) 2001-12-11
IT1291366B1 (it) 1999-01-07
DE69803565D1 (de) 2002-03-14
GEP20022672B (en) 2002-04-25

Similar Documents

Publication Publication Date Title
HU224956B1 (en) Pharmaceutical antiviral composition comprising glycyrrhizic acid and at least one protein endowed with antiviral activity
DE69110678T2 (de) Prophylaktische und therapeutische anwendungen von peroxidasen.
EP2046316B1 (en) Antiviral use of cationic surfactant
JPS59130223A (ja) 相乗作用を示す抗ヘルペス組成物
JP2023123440A (ja) 合成リジンアナログ及び模倣物の抗ウイルス用途のための方法及び組成物
US9149514B2 (en) Composition and method for treating papilloma virus and equine sarcoids
MXPA99010447A (en) Pharmaceutical antiviral composition comprising glycyrrhizic acid and at least one protein endowed with antiviral activity
HK1028347B (en) Pharmaceutical antiviral composition comprising glycyrrhizic acid and at least one protein endowed with antiviral activity
EP4620476A1 (en) Antiviral composition containing inclusion compounds with cyclodextrins as activity modulators and antiseptic actives and uses thereof
HK40026056A (en) Methods and compositions for the antiviral use of synthetic lysine analogs and mimetics

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees